Borderline Personality Disorder Treatment: DBT, MBT and Where Medication Fits

The main treatment for borderline personality disorder (BPD) is a structured psychotherapy designed for it, such as dialectical behavior therapy (DBT), mentalization-based treatment (MBT), transference-focused psychotherapy (TFP), schema therapy or good psychiatric management. The American Psychiatric Association's 2024 guideline recommends a structured, evidence-supported psychotherapy that targets the disorder's core features, and its authors report that no single therapy emerged as a gold standard. The guideline's executive summary was published in the American Journal of Psychiatry in November 2024.

Medication has a smaller role. No medication has been approved by regulators for BPD, and the APA found no evidence that any medicine treats the disorder's core symptoms. The guideline suggests that any medication be time-limited, aimed at a specific measurable symptom and added to psychotherapy, and recommends that medications be reviewed and reconciled at least every 6 months to identify any that should be tapered or stopped.

What BPD is, and why treatment is worth pursuing

BPD involves intense, fast-shifting emotions, an unstable sense of self, fear of abandonment, impulsive behavior and turbulent relationships. The APA estimates it affects 1.4% to 2.7% of people in the United States. People with BPD are more likely to self-harm, and many also live with depression, PTSD, bipolar disorder, anxiety, substance use or eating disorders.

The long-term outlook is better than its reputation. In a 10-year study of 290 people first assessed during a psychiatric hospitalization, 93% reached a symptom remission lasting at least 2 years and 86% a remission lasting at least 4 years; full recovery, meaning remission plus good social and work functioning, was harder, reached by 50%. Those numbers describe one group of patients, not a promise for any individual, but they counter the old idea that BPD is untreatable.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room. If self-harm or suicidal thinking is frequent, a written safety plan belongs in treatment from the start; the guide to safety planning for suicidal thoughts explains how one is built.

The evidence for psychotherapy as a whole

A 2020 Cochrane review pooled 75 randomized trials with 4,507 participants, most testing DBT or MBT. Compared with usual care, BPD-tailored psychotherapy reduced BPD symptom severity by a clinically meaningful amount, with smaller, less certain benefits for self-harm, suicide-related outcomes and day-to-day functioning. Subgroup analyses found no evidence that one therapy type outperformed the others against usual care.

That last finding is the practical message: the best therapy is often the well-delivered, structured one you can actually get and stay in. UK guidance makes a related point, advising against brief psychological interventions of under 3 months specifically for BPD outside a well-structured service.

The main therapies compared

Dialectical behavior therapy

DBT is the most studied BPD therapy: it was the subject of one-third of the trials in the 2020 Cochrane review, and it reduced self-harm compared with usual care, though that evidence was rated low quality. In a trial of women with BPD and recent suicidal and self-injurious behavior, with 1 year of treatment and 1 year of follow-up, those in DBT were half as likely to make a suicide attempt as those treated by community psychotherapy experts, needed fewer psychiatric hospitalizations and were less likely to drop out. A later trial that took DBT apart found that versions including skills training did better on self-injury, depression and anxiety than DBT individual therapy without skills training. UK guidance suggests a comprehensive DBT program for women with BPD when reducing recurrent self-harm is a priority.

"Comprehensive" matters. Standard DBT includes individual therapy, skills training, telephone coaching and a therapist consultation team. Many therapists offer DBT-informed individual work, which can be useful, but it is not the full program tested in trials. Ask which you would be getting. The site's posts on DBT versus CBT and DBT for borderline personality disorder describe the skills modules.

Mentalization-based treatment

In a randomized trial of 134 patients comparing outpatient MBT with structured clinical management, both groups improved substantially, but MBT patients showed a steeper decline in problems, including suicide attempts and hospitalization. The authors noted that MBT is relatively undemanding to train in, which may help it spread into general mental health services. MBT can suit people whose crises are driven by misreading others' intentions in close relationships.

Transference-focused and schema therapy

Both are longer-term individual therapies. In a 3-year randomized trial comparing them directly, both reduced BPD-specific and general symptoms and improved quality of life; schema therapy had fewer dropouts and better results on all measures. These approaches may appeal to people who want to work on deep patterns in relationships and identity and can commit to extended weekly or twice-weekly therapy.

Good psychiatric management

GPM was designed as a practical treatment that generalist clinicians can deliver. In a 1-year trial, people with BPD improved equally with DBT and with a well-specified general psychiatric management approach delivered by psychiatrists experienced with BPD. GPM is especially relevant where full DBT or MBT programs are not available, and it shows that a structured, informed clinician can provide effective care without a specialty brand.

Where medication fits

Medication is used, when it is used, for specific target symptoms or for co-occurring conditions such as major depression, not for BPD itself. The evidence is consistent across sources:

• A 2022 Cochrane review of 46 randomized trials found mostly very low-certainty evidence that medication made no difference on any primary outcome, and concluded that no medicine seems effective in specifically treating BPD pathology.
• The APA guideline recommends reviewing co-occurring disorders, past therapies and past medication trials before starting any new medicine, and suggests that any medication be time-limited, symptom-targeted and adjunctive to psychotherapy.
• UK guidance says drug treatment should not be used specifically for BPD or its individual symptoms, that antipsychotics should not be used for medium- and long-term treatment, and that short-term sedative use in a crisis should last no longer than 1 week.

Avoiding polypharmacy

People with BPD often accumulate medications: an antidepressant added during one crisis, an antipsychotic during another, a sedative after that. The APA authors said their pharmacotherapy findings led to recommendations designed to limit polypharmacy and prolonged treatment with medications. A review at least every 6 months asks whether each medicine still has a clear target and measurable benefit.

Never stop or reduce a medication on your own; some need gradual tapering, and the prescriber can plan changes safely. If you are on several medicines and unsure why, a second opinion on your psychiatric medication can help sort them out.

Co-occurring conditions and look-alikes

BPD often travels with other conditions. Some, such as major depression or PTSD, have their own effective treatments that can run alongside BPD-focused therapy. Others can be confused with BPD: bipolar disorder also involves mood instability, but it involves distinct episodes of mania or hypomania, while BPD mood shifts are often triggered by relationship events. Getting this distinction right changes the medication plan; see bipolar disorder medications compared. For trauma, PTSD therapies compared explains the options.

What the first months of treatment should include

The APA guideline sets out what good care looks like before any particular therapy begins.

• A thorough initial assessment covering your goals and preferences, symptoms and co-occurring conditions, past treatment, physical health, psychosocial and cultural factors, and risk of suicide, self-injury and aggression.
• A quantitative measure of symptom severity and functioning, so progress can be tracked rather than guessed.
• A documented, comprehensive, person-centered treatment plan.
• A collaborative conversation about the diagnosis, including education about the disorder.

That last point matters more than it may sound. Some people have carried the BPD label for years without anyone explaining it, or have been told it means they are "difficult." A clinician who explains the diagnosis openly, including its good long-term outlook, sets up a very different working relationship.

What the evidence does not show

The research base is real but has gaps worth knowing. Most trial participants have been women, and the Cochrane review of medications called for more research in men and adolescents and in people with co-occurring trauma, depression, substance use and eating disorders. For self-harm and suicide-related outcomes, the psychotherapy evidence was rated low quality, and the average improvement did not reach the threshold the reviewers set for clinical relevance, even though it favored therapy. Long-term comparisons between specific therapies are few. None of this means therapy does not work; it means expectations should be realistic and progress should be measured in your own treatment.

A worked example

Consider a hypothetical adult, an illustration rather than a real patient. She has had several emergency visits after self-harm, takes four psychiatric medicines started during different crises, and has tried brief counseling twice without lasting change.

• Her new clinician reviews her history, explains the BPD diagnosis and its outlook, and builds a safety plan.
• Because recurrent self-harm is the priority, they look for a comprehensive DBT program with skills group and phone coaching.
• Her prescriber reviews each medicine against a specific target. One is clearly helping a co-occurring depression and stays; two with no clear benefit are tapered gradually over the following months under supervision.
• They agree to review symptoms and medications at least every 6 months.

If no full DBT program had been available, a clinician trained in MBT or good psychiatric management would have been a reasonable alternative.

Choosing a therapist or program

• Ask what model they use and what training they have in it.
• For DBT, ask whether the program includes a skills group, between-session phone coaching and a consultation team, or is DBT-informed individual therapy.
• Ask how they handle crises and self-harm, including what happens between sessions.
• Ask how long treatment usually lasts and how progress is measured; how long therapy takes gives typical ranges.
• Ask how they coordinate with a prescriber, if you have one.
• If self-harm or suicide risk is high, ask whether a more intensive level of care is needed first; see levels of mental health care.

Group work is part of several models; the guide to group versus individual therapy covers what to expect. For teens, adapted DBT programs exist; the site's post on DBT for teens describes one approach.

How Dr. Lewis's practice approaches BPD treatment

The practice's psychotherapy services include CBT and DBT, alongside psychiatric evaluation and medication management. Its team includes psychiatrists, psychiatric nurse practitioners and psychotherapists, which can make it easier for therapy and any medication review to be coordinated. Ask on the free discovery call whether the practice's DBT includes a skills group and phone coaching or is DBT-informed individual therapy, so you know which you would receive. The practice's DBT page and psychotherapy page describe its approach, and the guide to choosing psychiatric care covers the wider decision.

Frequently asked questions

Is there an FDA-approved medication for borderline personality disorder?

No. No medication has been approved by regulators for BPD. Medicines are sometimes used for specific symptoms or for co-occurring conditions such as depression, as an adjunct to psychotherapy.

Is DBT the only therapy that works for BPD?

No. DBT has the most research, especially for self-harm, but MBT, schema therapy, transference-focused psychotherapy and good psychiatric management also have trial support, and the APA found no single gold-standard therapy.

How long does BPD treatment take?

In the trials pooled by a 2020 Cochrane review, treatment lasted from one month to three years, and several well-known programs run a year or longer. Many people notice changes in crisis frequency earlier, but lasting change in patterns and relationships usually takes longer.

Can BPD go away?

Many people improve substantially. In one long-term study most patients achieved lasting symptom remission over 10 years, though fewer achieved full recovery including good social and work functioning. Outcomes differ by person.

Should family members be involved?

Often it helps, with the person's agreement. Some programs offer family skills or education sessions, and family members can learn how to respond to crises without reinforcing them.

What if I cannot find a full DBT program?

Other structured treatments, including good psychiatric management and MBT, also have support from randomized trials, and one trial found good psychiatric management as helpful as DBT over a year. A clinician trained in any structured BPD approach is a reasonable starting point.

Sources

1. American Psychiatric Association Publishes Updated Practice Guideline on the Treatment of Borderline Personality Disorder. American Psychiatric Association, news release, 2024. psychiatry.org
2. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. American Journal of Psychiatry 181(11):1024-1028 (Keepers et al.), 2024. pubmed.ncbi.nlm.nih.gov
3. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews CD012955 (Storebø et al.), 2020. pubmed.ncbi.nlm.nih.gov
4. Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews CD012956 (Stoffers-Winterling et al.), 2022. pubmed.ncbi.nlm.nih.gov
5. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry 63(7):757-66 (Linehan et al.), 2006. pubmed.ncbi.nlm.nih.gov
6. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry (Linehan et al.), 2015. pubmed.ncbi.nlm.nih.gov
7. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry 166(12):1355-64 (Bateman and Fonagy), 2009. pubmed.ncbi.nlm.nih.gov
8. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry 63(6):649-58 (Giesen-Bloo et al.), 2006. pubmed.ncbi.nlm.nih.gov
9. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 166(12):1365-74 (McMain et al.), 2009. pubmed.ncbi.nlm.nih.gov
10. Borderline personality disorder: recognition and management (CG78), Recommendations. National Institute for Health and Care Excellence (NICE), 2009, reviewed 2024. nice.org.uk
11. Time to attainment of recovery from borderline personality disorder and stability of recovery: A 10-year prospective follow-up study. American Journal of Psychiatry 167(6):663-7 (Zanarini et al.), 2010. pubmed.ncbi.nlm.nih.gov
12. Borderline Personality Disorder. National Institute of Mental Health, 2024. nimh.nih.gov
13. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis. CNS Drugs 35(10):1053-1067 (Gartlehner et al.), 2021. pmc.ncbi.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.